2013 Fiscal Year Final Research Report
The strategy to avoid drug-induced skeletal muscle injury involved in monocarboxylate transporter
| Project/Area Number |
24790138
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
KOBAYASHI Masaki 北海道大学, 薬学研究科(研究院), 助教 (70431319)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Keywords | 薬剤性筋障害 / 乳酸トランスポーター |
|---|
| Research Abstract |
Although exercise and drug therapy is important to prevent progress of an arteriosclerotic disease, exercise performance leads to increase drug-induced muscle injury. So the elucidation of this mechanism is needed for avoiding muscular disorder. Since exercise performance induced the expression of monocarboxylate transporter (MCT) 4, we focused on the association between MCT4 and HMG-CoA reductase inhibitors such as statins-induced muscle injury. Atorvastatin, one of statins reduced the number of viable cells and caused dramatic morphological changes and caspase-3/7 activation, and induced MCT4 expression levels in RD cell line as a model of in vitro skeletal muscle. Two siRNAs (10 nM) for MCT4 significantly decreased MCT4 expression at 72 h after transfected to RD cells. Atorvastatin-induced RD cell injury was blocked by MCT4 siRNAs transfected to RD cells. These results suggest that the mechanism of statin-induced muscle injury was associated with MCT4 expression.
|
Research Products
(5 results)
-
-
[Journal Article] Regulation of the expression and activity of glucose and lactic acid metabolism-related genes by protein kinase C (PKC) in skeletal muscle cells2013
Author(s)
Otake S, Kobayashi M, Narumi K, Sasaki S, Kikutani Y, Furugen A, Watanabe M, Takahashi N, Ogura J, Yamaguchi H, Iseki K
-
Journal Title
Biol Pharm Bull
Volume: 36
Pages: 1435-9
DOI
Peer Reviewed
-
-
-
